Quick Answer
Tectonic Therapeutic, Inc. reported Research And Development Expense of $63.49 million for the year ending 2025.
- Tectonic Therapeutic, Inc. showed an increase of +53.5% in Research And Development Expense from 2024 to 2025.
- This data is from Tectonic Therapeutic, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $1.88 million | Q3 2017: $5.41 million | Q1 2018: $5.65 million | Q2 2018: $7.41 million | Q3 2018: $9.23 million | Q1 2019: $12.45 million | Q2 2019: $12.27 million | Q3 2019: $13.04 million | Q1 2020: $18.27 million | Q2 2020: $20.87 million | Q3 2020: $28.51 million | Q1 2021: $18.53 million | Q2 2021: $22.54 million | Q3 2021: $23.04 million | Q1 2022: $19.25 million | Q2 2022: $18.88 million | Q3 2022: $15.92 million | Q1 2023: $17.33 million | Q2 2023: $8.77 million | Q3 2023: $8.13 million | Q1 2024: $10.82 million | Q2 2024: $7.07 million | Q3 2024: $14.32 million | Q1 2025: $13.04 million | Q2 2025: $17.19 million | Q3 2025: $16.93 million.
- Over the full 9 years of available data (2017 to 2025), Tectonic Therapeutic, Inc.'s Research And Development Expense has grown by 317.9%.
- Historical annual values: Fiscal year 2025: $63.49 million | Fiscal year 2024: $41.36 million | Fiscal year 2023: $36.97 million | Fiscal year 2022: $72.19 million | Fiscal year 2021: $83.11 million | Fiscal year 2020: $87.24 million | Fiscal year 2019: $54.97 million | Fiscal year 2018: $35.10 million | Fiscal year 2017: $15.19 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: